FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567743054> ?p ?o ?g. }

• W2567743054 endingPage "S9" @default.
• W2567743054 startingPage "S8" @default.
• W2567743054 abstract "In KEYNOTE-024 (NCT02142738), pembrolizumab provided superior progression-free survival (PFS) over platinum-based chemotherapy as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression on ≥50% of tumor cells (ie, PD-L1 tumor proportion score [TPS] ≥50%) and no sensitizing EGFR or ALK aberrations (HR 0.50, P < 0.001). Despite a 44% crossover rate from chemotherapy to pembrolizumab, pembrolizumab also significantly improved overall survival (OS) (HR 0.60, P = 0.005). Any-grade (73% vs 90%) and grade 3-5 (27% vs 53%) treatment-related adverse events were less frequent with pembrolizumab. Health-related quality of life (HRQoL) is an important consideration for anticancer therapy, particularly in the first-line setting. We present data from the prespecified exploratory patient-reported outcomes (PRO) analysis of KEYNOTE-024. 305 patients were randomized to pembrolizumab 200 mg Q3W or investigator-choice platinum-doublet chemotherapy plus optional pemetrexed maintenance therapy for nonsquamous disease. The EORTC QLQ-C30 and QLQ-LC13 were administered at cycles 1-3 and every 9 weeks thereafter. The key PRO end points were change from baseline to week 15 in the QLQ-C30 global health status/QoL score and time to deterioration in the QLQ-LC13 composite of cough, chest pain, and dyspnea. PROs were analyzed for all patients who received study treatment and completed ≥1 PRO instrument (n = 299). Across treatment arms, PRO compliance was >90% at baseline and ∼80% at week 15. Least squares (LS) mean (95% CI) change from baseline to week 15 in QLQ-C30 global health status/QoL score was 6.95 (3.29 to10.58) for pembrolizumab (n = 151) and –0.88 (–4.78 to 3.02) for chemotherapy (n = 148). The difference in LS means was 7.82 (95% CI 2.85-12.79; nominal 2-sided P = 0.002). The proportion of improved global health status/QoL score at week 15 was 40.0% for pembrolizumab and 26.5% for chemotherapy. Fewer patients in the pembrolizumab arm had deterioration in the QLQ-LC13 composite of cough, dyspnea, and chest pain (30% vs 39%), and time to deterioration was also prolonged with pembrolizumab (HR 0.66, 95% CI 0.44-0.97; nominal 2-sided P = 0.029). Pembrolizumab was associated with a clinically meaningful improvement in HRQoL compared with platinum-based chemotherapy. Combined with the superior PFS and OS and manageable safety profile, these data suggest pembrolizumab may be a new standard of care for first-line treatment of PD-L1–expressing advanced NSCLC." @default.
• W2567743054 created "2017-01-13" @default.
• W2567743054 creator A5001503641 @default.
• W2567743054 creator A5003944586 @default.
• W2567743054 creator A5004864286 @default.
• W2567743054 creator A5010421355 @default.
• W2567743054 creator A5018401879 @default.
• W2567743054 creator A5018757509 @default.
• W2567743054 creator A5033474030 @default.
• W2567743054 creator A5039952118 @default.
• W2567743054 creator A5042196666 @default.
• W2567743054 creator A5055174519 @default.
• W2567743054 creator A5055964030 @default.
• W2567743054 creator A5059513209 @default.
• W2567743054 creator A5060572768 @default.
• W2567743054 creator A5062920555 @default.
• W2567743054 creator A5068491805 @default.
• W2567743054 creator A5073078501 @default.
• W2567743054 creator A5075510355 @default.
• W2567743054 creator A5088655911 @default.
• W2567743054 date "2017-01-01" @default.
• W2567743054 modified "2023-10-18" @default.
• W2567743054 title "PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024" @default.
• W2567743054 doi "https://doi.org/10.1016/j.jtho.2016.11.010" @default.
• W2567743054 hasPublicationYear "2017" @default.
• W2567743054 type Work @default.
• W2567743054 sameAs 2567743054 @default.
• W2567743054 citedByCount "10" @default.
• W2567743054 countsByYear W25677430542017 @default.
• W2567743054 countsByYear W25677430542018 @default.
• W2567743054 countsByYear W25677430542019 @default.
• W2567743054 countsByYear W25677430542020 @default.
• W2567743054 countsByYear W25677430542021 @default.
• W2567743054 countsByYear W25677430542023 @default.
• W2567743054 crossrefType "journal-article" @default.
• W2567743054 hasAuthorship W2567743054A5001503641 @default.
• W2567743054 hasAuthorship W2567743054A5003944586 @default.
• W2567743054 hasAuthorship W2567743054A5004864286 @default.
• W2567743054 hasAuthorship W2567743054A5010421355 @default.
• W2567743054 hasAuthorship W2567743054A5018401879 @default.
• W2567743054 hasAuthorship W2567743054A5018757509 @default.
• W2567743054 hasAuthorship W2567743054A5033474030 @default.
• W2567743054 hasAuthorship W2567743054A5039952118 @default.
• W2567743054 hasAuthorship W2567743054A5042196666 @default.
• W2567743054 hasAuthorship W2567743054A5055174519 @default.
• W2567743054 hasAuthorship W2567743054A5055964030 @default.
• W2567743054 hasAuthorship W2567743054A5059513209 @default.
• W2567743054 hasAuthorship W2567743054A5060572768 @default.
• W2567743054 hasAuthorship W2567743054A5062920555 @default.
• W2567743054 hasAuthorship W2567743054A5068491805 @default.
• W2567743054 hasAuthorship W2567743054A5073078501 @default.
• W2567743054 hasAuthorship W2567743054A5075510355 @default.
• W2567743054 hasAuthorship W2567743054A5088655911 @default.
• W2567743054 hasBestOaLocation W25677430541 @default.
• W2567743054 hasConcept C121608353 @default.
• W2567743054 hasConcept C126322002 @default.
• W2567743054 hasConcept C143998085 @default.
• W2567743054 hasConcept C159110408 @default.
• W2567743054 hasConcept C197934379 @default.
• W2567743054 hasConcept C2776256026 @default.
• W2567743054 hasConcept C2776694085 @default.
• W2567743054 hasConcept C2777240266 @default.
• W2567743054 hasConcept C2777701055 @default.
• W2567743054 hasConcept C2778239845 @default.
• W2567743054 hasConcept C2779951463 @default.
• W2567743054 hasConcept C2780057760 @default.
• W2567743054 hasConcept C2780739268 @default.
• W2567743054 hasConcept C71924100 @default.
• W2567743054 hasConceptScore W2567743054C121608353 @default.
• W2567743054 hasConceptScore W2567743054C126322002 @default.
• W2567743054 hasConceptScore W2567743054C143998085 @default.
• W2567743054 hasConceptScore W2567743054C159110408 @default.
• W2567743054 hasConceptScore W2567743054C197934379 @default.
• W2567743054 hasConceptScore W2567743054C2776256026 @default.
• W2567743054 hasConceptScore W2567743054C2776694085 @default.
• W2567743054 hasConceptScore W2567743054C2777240266 @default.
• W2567743054 hasConceptScore W2567743054C2777701055 @default.
• W2567743054 hasConceptScore W2567743054C2778239845 @default.
• W2567743054 hasConceptScore W2567743054C2779951463 @default.
• W2567743054 hasConceptScore W2567743054C2780057760 @default.
• W2567743054 hasConceptScore W2567743054C2780739268 @default.
• W2567743054 hasConceptScore W2567743054C71924100 @default.
• W2567743054 hasIssue "1" @default.
• W2567743054 hasLocation W25677430541 @default.
• W2567743054 hasOpenAccess W2567743054 @default.
• W2567743054 hasPrimaryLocation W25677430541 @default.
• W2567743054 hasRelatedWork W2894792775 @default.
• W2567743054 hasRelatedWork W2981688104 @default.
• W2567743054 hasRelatedWork W3004989554 @default.
• W2567743054 hasRelatedWork W3011176692 @default.
• W2567743054 hasRelatedWork W3094659495 @default.
• W2567743054 hasRelatedWork W3196861824 @default.
• W2567743054 hasRelatedWork W3207533547 @default.
• W2567743054 hasRelatedWork W4286294620 @default.
• W2567743054 hasRelatedWork W4308399177 @default.
• W2567743054 hasRelatedWork W4313857758 @default.
• W2567743054 hasVolume "12" @default.
• W2567743054 isParatext "false" @default.

• next